Dr. Christine M. Lovly, MD, PhD

Dr. Lovly practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Lovly's NPI, 1265589071, was assigned on January 4, 2007. Dr. Lovly holds Tennessee license 48883.

Dr. Lovly's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Lovly's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Lovly is also affiliated with Vanderbilt University Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Lovly to 1 more other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lovly practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lovly's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lovly is licensed in Tennessee.

CMS data shows 59 Medicare services from Dr. Lovly across 2 procedure codes in 2024, all of them office visits, for 41 Medicare patients. Medicare paid $6,611 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 41 Medicare patients who saw Dr. Lovly in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lovly's median patient age at 72, with 57% women.

In 2024, Dr. Lovly wrote 57 Medicare Part D claims for 11 patients. 51% of them were for generic drugs. CMS names the drug for 25 of them, across 2 drugs with 11 or more claims each, at $446,048 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

Dr. Lovly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lovly as offering telehealth.

CMS Open Payments shows 323 general payments to Dr. Lovly from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $57,225. It also lists 3 research payments totaling $1,322 from 2021 to 2024.